KR20130008092A - 암 치료에서 다중약물 내성 억제용 ｐ-당단백질 170에 대한 표적 치료학적 백신 - Google Patents

암 치료에서 다중약물 내성 억제용 ｐ-당단백질 170에 대한 표적 치료학적 백신 Download PDF

Info

Publication number
KR20130008092A
KR20130008092A KR1020127033292A KR20127033292A KR20130008092A KR 20130008092 A KR20130008092 A KR 20130008092A KR 1020127033292 A KR1020127033292 A KR 1020127033292A KR 20127033292 A KR20127033292 A KR 20127033292A KR 20130008092 A KR20130008092 A KR 20130008092A
Authority
KR
South Korea
Prior art keywords
peptide
conjugate
protein
treatment
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020127033292A
Other languages
English (en)
Korean (ko)
Inventor
클라우딘 마둘렛
피에르-프랑수아 토시
클라우데 니꼴라우
데이비드 티. 힉크만
Original Assignee
에이씨 이뮨 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에이씨 이뮨 에스.에이. filed Critical 에이씨 이뮨 에스.에이.
Publication of KR20130008092A publication Critical patent/KR20130008092A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Dispersion Chemistry (AREA)
KR1020127033292A 2003-07-25 2004-07-25 암 치료에서 다중약물 내성 억제용 ｐ-당단백질 170에 대한 표적 치료학적 백신 Ceased KR20130008092A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0309188A FR2857875A1 (fr) 2003-07-25 2003-07-25 Vaccin therapeutique cible contre la p-glycoproteine 170 pour inhiber la resistance multidrogues dans le traitement des cancers
FR0309188 2003-07-25
PCT/EP2004/008330 WO2005014036A1 (fr) 2003-07-25 2004-07-25 Vaccin therapeutique cible contre la p-glycoproteine 170 pour inhiber la resistance multidrogues dans le traitement des cancers

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020067001783A Division KR20060125676A (ko) 2003-07-25 2004-07-25 암 치료에서 다중약물 내성 억제용 ｐ-당단백질 170에 대한표적 치료학적 백신

Publications (1)

Publication Number Publication Date
KR20130008092A true KR20130008092A (ko) 2013-01-21

Family

ID=33561147

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020127033292A Ceased KR20130008092A (ko) 2003-07-25 2004-07-25 암 치료에서 다중약물 내성 억제용 ｐ-당단백질 170에 대한 표적 치료학적 백신
KR1020067001783A Ceased KR20060125676A (ko) 2003-07-25 2004-07-25 암 치료에서 다중약물 내성 억제용 ｐ-당단백질 170에 대한표적 치료학적 백신

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020067001783A Ceased KR20060125676A (ko) 2003-07-25 2004-07-25 암 치료에서 다중약물 내성 억제용 ｐ-당단백질 170에 대한표적 치료학적 백신

Country Status (9)

Country Link
US (1) US20060233758A1 (enExample)
EP (2) EP1651257B1 (enExample)
JP (2) JP2006528650A (enExample)
KR (2) KR20130008092A (enExample)
CN (1) CN1856323B (enExample)
AU (1) AU2004262472B2 (enExample)
CA (1) CA2533540C (enExample)
FR (1) FR2857875A1 (enExample)
WO (1) WO2005014036A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
US20080026995A1 (en) * 2003-07-25 2008-01-31 Ac Immune Sa Therapeutic vaccine targeted against p-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
US7807171B2 (en) * 2003-07-25 2010-10-05 Ac Immune Sa Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
US8090392B2 (en) * 2005-08-05 2012-01-03 Interdigital Technology Corporation Method and system for reporting a short message capability via an IP multimedia subsystem
EP2468300B1 (en) 2006-09-26 2017-12-20 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
KR101130754B1 (ko) * 2010-06-25 2012-03-28 제일약품주식회사 난용성 트리사이클릭 유도체 화합물의 용해도가 향상된 약학적 조성물
WO2012020124A1 (en) 2010-08-12 2012-02-16 Ac Immune S.A. Vaccine engineering
EP2632434B1 (en) 2010-10-26 2025-08-20 AC Immune S.A. Liposome-based construct comprising a peptide modified through hydrophobic moieties
SMT201800368T1 (it) 2012-05-16 2018-09-13 Immune Design Corp Vaccini per l'infezione da virus-2 herpes simplex
CA2909221A1 (en) 2013-04-18 2014-10-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
CA3118692A1 (en) 2018-11-06 2020-05-14 Alsatech, Inc. Cell-based gene therapy for neurodegenerative diseases
CN112687354B (zh) * 2019-01-29 2022-07-12 杭州纽安津生物科技有限公司 针对靶向药物PI3K、AKT、mTOR通路的激酶抑制剂的多肽疫苗组合及其设计方法
CN115968376A (zh) * 2020-04-17 2023-04-14 I2O治疗公司 长效胰高血糖素受体选择性肽和使用方法
CN113648429B (zh) * 2021-07-06 2023-11-10 中山大学 靶向肿瘤周围细胞激活免疫的聚合物及其制备方法与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1257893B (it) * 1992-06-17 1996-02-16 Ist Superiore Sanita Anticorpi monoclonali che riconoscono un epitopo della p-glicoproteina umana.
WO1994010198A1 (en) * 1992-11-02 1994-05-11 Yves Claude Nicolau Method of reducing multidrug resistance in cells and tissues
JP3759759B2 (ja) * 1994-03-04 2006-03-29 日本油脂株式会社 リポソームおよび薬物運搬体
JP4385152B2 (ja) * 1997-09-17 2009-12-16 三菱化学株式会社 ２価反応性水溶性高分子誘導体及びそれを含有する複合体
JP2002047298A (ja) * 2000-07-10 2002-02-12 Academia Sinica 新規抗がん剤伝達系
US8663650B2 (en) * 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
CN1849141A (zh) * 2003-05-12 2006-10-18 阿费麦克斯公司 用于聚(乙二醇)修饰的肽的间隔臂部分

Also Published As

Publication number Publication date
CA2533540A1 (fr) 2005-02-17
JP2006528650A (ja) 2006-12-21
JP2013121977A (ja) 2013-06-20
EP1651257A1 (fr) 2006-05-03
KR20060125676A (ko) 2006-12-06
CA2533540C (fr) 2016-02-23
CN1856323B (zh) 2013-12-25
CN1856323A (zh) 2006-11-01
WO2005014036A1 (fr) 2005-02-17
AU2004262472A2 (en) 2005-02-17
EP1651257B1 (fr) 2016-02-17
AU2004262472A1 (en) 2005-02-17
EP2316478A1 (fr) 2011-05-04
EP2316478B1 (fr) 2017-04-26
FR2857875A1 (fr) 2005-01-28
US20060233758A1 (en) 2006-10-19
AU2004262472B2 (en) 2011-07-14

Similar Documents

Publication Publication Date Title
US8409580B2 (en) Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
JP2013121977A (ja) 癌の治療における多剤耐性を抑制するための、ｐ−糖タンパク質１７０を標的とする治療ワクチン
TWI252233B (en) Immunogenic peptide composition for the prevention and treatment of Alzheimer's disease
JP5519477B2 (ja) Ｔ１免疫応答とｔ２免疫応答との間で調節するためのワクチン
US6238667B1 (en) Method of affinity cross-linking biologically active immunogenic peptides to antibodies
JP7071570B2 (ja) Ｍｈｃ－ｉの発現を増加させるためのクルクフェノール化合物
US20040052809A1 (en) Vaccine
CZ20013709A3 (cs) Analog interleukinu 5, fragment nukleové kyseliny, vektor, buňka, přípravky a pouľití
US7169898B2 (en) Soluble CD83 proteins and use thereof for the treatment or prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells
US20060104943A1 (en) Vaccine comprising il-13 and an adjuvant
WO2013123282A1 (en) Xenoantigen-displaying anti-cancer vaccines and method of making
US20080026995A1 (en) Therapeutic vaccine targeted against p-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
AU2002309141A1 (en) Vaccine for modulating between T1 and T2 immune responses
US20050244419A1 (en) Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
US20050255561A1 (en) Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
JP2015525785A (ja) 腫瘍治療のためのペプチドＥＧＦＲｖＩＩＩ配列に基づくワクチン
WO2013088141A1 (en) Polypeptide comprising the sequence egpwleeeeeayg linked to an immunogenic carrier
HK1096577A (en) Targeted therapeutic vaccine against p-glycoprotein 170 for inhibiting multi-drug resistance in the treatment of cancers
WO2007056304A2 (en) Mutated forms of ny-eso-1 produced in yeast and uses thereof

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20121220

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20130111

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130401

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20131007

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20130401

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I